AKTX
Akari Therapeutics, Plc NASDAQ Listed Jan 6, 2014$7.90
+5.04%
vs $7.52
Mkt Cap $6.6M
52w Low $3.06
11.6% of range
52w High $44.80
50d MA $10.50
200d MA $10.96
P/E (TTM)
-0.0x
EV/EBITDA
—
P/B
0.2x
Debt/Equity
0.0x
ROE
-61.1%
P/FCF
-0.6x
RSI (14)
46.90
ATR (14)
$0.76
Beta
0.54
50d MA
$10.50
200d MA
$10.96
Avg Volume
46.1K
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
75/76 Wimpole Street · London, FL W1G 9RT · GB
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | AMC | -1.04 | -272.00 | -9999.0% | 7.00 | +0.1% | +7.7% | -0.3% | +5.0% | — | — | — |
| May 19, 2026 | AMC | -1.33 | -9.74 | -632.3% | 3.74 | -0.3% | -8.3% | +49.9% | +255.4% | -2.5% | -10.6% | — |
| Apr 7, 2026 | AMC | -1.80 | -2.99 | -66.1% | 3.80 | -0.5% | +2.1% | +1.0% | -2.3% | +11.0% | +8.9% | — |
| Mar 30, 2026 | AMC | -1.80 | -2.99 | -66.1% | 4.84 | +3.1% | +6.4% | -9.7% | -3.9% | -20.8% | +7.3% | — |
| Nov 13, 2025 | AMC | -1.60 | -4.00 | -150.0% | 20.80 | +7.7% | +1.7% | -10.4% | +12.0% | -6.0% | -7.3% | — |
| Aug 13, 2025 | AMC | -3.60 | -2.40 | +33.3% | 39.30 | +1.8% | -1.3% | +4.1% | -1.0% | -0.9% | -4.2% | — |
| May 15, 2025 | AMC | — | -5.40 | — | 52.80 | -7.6% | -3.8% | -0.8% | +3.2% | -4.6% | +0.8% | — |
| May 14, 2025 | AMC | — | -0.14 | — | 54.00 | -3.7% | -2.2% | -3.8% | -0.8% | +3.2% | -4.6% | — |
| Apr 16, 2025 | AMC | -40.00 | -6.80 | +83.0% | 44.00 | +0.0% | +10.0% | +5.8% | +6.2% | +6.6% | +0.7% | — |
| Apr 14, 2025 | AMC | -1.00 | -0.17 | +83.0% | 44.40 | +14.4% | +8.1% | -8.3% | +10.0% | +5.8% | +6.2% | — |
| Nov 19, 2024 | AMC | -0.60 | -472.00 | -9999.0% | 62.80 | +7.0% | -6.4% | -15.6% | +4.8% | -20.8% | +10.7% | — |
| Aug 19, 2024 | AMC | -40.00 | -1608.00 | -3920.0% | 144.00 | -6.4% | -0.3% | +0.0% | +3.3% | +3.5% | -1.0% | — |
| May 15, 2024 | AMC | -40.00 | -1656.00 | -4040.0% | 58.40 | -1.4% | +1.4% | +2.7% | +0.0% | +7.9% | +16.5% | — |
| Mar 29, 2024 | AMC | — | -2.40 | — | — | — | — | — | — | — | — | — |
| Jan 8, 2024 | AMC | — | -1880.00 | — | 121.20 | -0.7% | -1.0% | -2.7% | -1.0% | -0.3% | +0.0% | — |
| Oct 10, 2023 | AMC | -0.60 | -1136.00 | -9999.0% | 142.80 | +2.0% | +1.1% | -2.8% | +4.0% | -5.6% | -1.1% | — |
| Oct 3, 2023 | AMC | -0.60 | -2.40 | -300.0% | 153.60 | -4.9% | -5.2% | +0.0% | +1.7% | -0.9% | -2.7% | — |
| Sep 26, 2023 | AMC | -1.00 | 2.00 | +300.0% | 162.00 | -6.9% | +0.0% | +0.7% | -3.2% | -8.6% | +6.3% | — |
| Jul 19, 2023 | AMC | -0.07 | -0.10 | -42.9% | 140.80 | -1.7% | -0.6% | -0.6% | +0.0% | +8.0% | +4.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 20 | Maxim Group | Upgrade | Hold → Buy | $30 | $11.01 | $11.49 | +4.4% | -3.2% | -12.8% | +5.5% | -5.2% | -6.5% |
| Apr 8 | Maxim Group | Downgrade | Buy → Hold | — | $3.80 | $3.78 | -0.5% | +2.1% | +1.0% | -2.3% | +11.0% | +8.9% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.15 | $5.15 | +0.0% | -9.7% | -3.9% | -20.8% | +7.3% | +2.1% |
| Sep 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.00 | $35.44 | +4.2% | -1.2% | -6.0% | -2.5% | +2.5% | -1.7% |
| Dec 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $431.20 | $460.00 | +6.7% | +3.7% | -3.4% | +5.6% | -7.0% | -0.8% |
| Nov 1 | Alliance Global Partners | Maintains | Buy → Buy | — | $372.80 | $380.00 | +1.9% | +1.1% | +4.0% | +0.0% | -0.4% | +0.4% |
| Mar 13 | B. Riley FBR | Maintains | Buy → Buy | — | $1104.00 | $1128.00 | +2.2% | -8.7% | -15.9% | +18.9% | -2.1% | +2.8% |
| Mar 13 | B. Riley Securities | Maintains | Buy → Buy | — | $1104.00 | $1128.00 | +2.2% | -8.7% | -15.9% | +18.9% | -2.1% | +2.8% |
| Mar 12 | B. Riley Securities | Maintains | Buy → Buy | — | $1233.60 | $1200.00 | -2.7% | -10.5% | -8.7% | -15.9% | +18.9% | -2.1% |
| May 5 | B. Riley FBR | Maintains | Neutral → Neutral | — | — | — | — | — | — | — | — | — |
| Mar 29 | Canaccord Genuity | Maintains | Buy → Buy | — | $1416.00 | $1408.00 | -0.6% | +2.8% | +1.1% | -2.2% | +0.0% | +9.4% |
| Feb 8 | B. Riley FBR | Maintains | Neutral → Neutral | — | $1752.00 | $1760.00 | +0.5% | +4.6% | +1.3% | +9.9% | -5.5% | +0.4% |
| Sep 22 | William Blair | Upgrade | Market Perform → Outperform | — | $6992.00 | $7864.00 | +12.5% | -6.4% | -11.0% | -2.3% | -3.4% | -8.2% |
| May 31 | Chardan Capital | Upgrade | Sell → Neutral | — | $4712.00 | $4920.00 | +4.4% | +4.1% | +1.6% | +7.9% | -9.5% | -1.5% |
| May 12 | William Blair | Downgrade | Outperform → Market Perform | — | $9192.00 | $7440.00 | -19.1% | -21.4% | +0.9% | -11.4% | -4.8% | -3.4% |
| May 11 | William Blair | Downgrade | Outperform → Perform | — | $8800.00 | $8944.00 | +1.6% | +4.5% | -21.4% | +0.9% | -11.4% | -4.8% |
| Apr 17 | Chardan Capital | Maintains | Sell → Sell | — | $12816.00 | $12088.00 | -5.7% | -16.9% | +12.5% | -7.9% | +18.7% | +25.2% |
| Jul 11 | Chardan Capital | Maintains | Sell → Sell | — | $9623.20 | $8800.00 | -8.6% | -8.1% | +1.4% | +3.6% | -3.2% | -12.7% |
No insider trades available.
8-K
Akari Therapeutics, Plc -- 8-K Filing
Jul 2
8-K
Akari Therapeutics, Plc -- 8-K Filing
Jun 26
NT 10-Q
!! High
Akari Therapeutics, Plc -- Late Quarterly Report -- Distress Signal
May 18
8-K
Akari Therapeutics plc ADR (0.01 USD) -- 8-K Filing
Akari Therapeutics completed private placement financings in December 2025 and January 2026, securing capital to fund operations and development initiatives.
Mar 2
Institutional (13F) — Top 3
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Ifp Advisors, Inc | 181 | $2K | — | Jun 2026 |
| 2 | Sbi Securities Co., Ltd. | 14 | $143 | New | Jun 2026 |
| 3 | Caitong International Asset Management Co., Ltd | 8 | $82 | New | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 0
All ↗
No N-PORT holders found.
Valuation
Market Cap
$6.6M
Enterprise Value
$1.4M
P/E (TTM)
-0.01x
Forward P/E
—
PEG Ratio
0.00x
P/B
0.23x
P/S
—
P/FCF
-0.63x
EV/EBITDA
—
Shares Out
842K
Financials (TTM)
Revenue
$0
Net Income
-$28.0M
EBITDA
-$29.0M
Free Cash Flow
-$10.6M
Op Cash Flow
-$10.6M
EPS Basic
$-20800.00
EPS Diluted
$-1448.00
EPS Forward
$-5.77
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$47.9M
Total Liab.
$19.6M
Total Equity
$28.3M
Cash
$5.2M
LT Debt
$0
Book Value/Sh
$33.66
Debt/Equity
0.03x
Current Ratio
0.44
Quick Ratio
0.44
Returns & Growth
ROE
-61.1%
ROA
-36.1%
ROIC
-45.0%
Rev Growth YoY
+0.0%
EPS Growth YoY
-32400.0%
Price Returns
2W
+2.2%
1M
-31.7%
3M
+114.9%
6M
-21.7%
12M
-81.2%
Technicals
52W High
$44.80
52W Low
$3.06
50d MA
$10.50
200d MA
$10.96
RSI (14)
46.90
ATR (14)
$0.76
Beta
0.54
Avg Volume
46K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$1200.00
High
$1200.00
Low
$1200.00
Median
$1200.00
Data updated apr 26, 2026 9:31am
· Source: financialmodelingprep.com